Split Decision as COPD Drug Itepekimab Fails One Clinical Trial
Sanofi and Regeneron's COPD drug candidate itepekimab met its primary endpoint in one phase 3 study but failed in a second trial.
Tag: Regeneron Pharma
Split Decision as COPD Drug Itepekimab Fails One Clinical Trial
Sanofi and Regeneron’s COPD drug candidate itepekimab met its primary endpoint in one phase 3 study but failed in a second trial.
Read More
FDA Approves Dupixent for Chronic Rhinosinusitis with Nasal Polyps in Adolescents
The FDA has approved Dupixent as an add-on maintenance treatment for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps, expanding its original approval for adults in 2019.
Read More
Sanofi Gets Asthma Treatment Approval for Pediatric Patients in Canada
Sanofi and Regeneron Pharmaceuticals’ Dupixent was approved in Canada for expanded use as an add-on maintenance treatment in certain patients with severe asthma.
Read More
Investigational Dupilumab Could Treat Asthma Exacerbations
A novel approach to obstructing the runaway inflammatory response implicated in certain types of asthma holds promise, according to Phase II-a trial results for dupilumab, a monoclonal antibody.
Read More